The trial of the Code 19 vaccine, developed under the auspices of the University of Oxford in the United Kingdom, began in April.
Now the leading scientist who developed the vaccine says his team has seen in trials the correct immune response of volunteers to the corona virus.
Sarah Gilbert, an Oxford professor of vaccineology, said 8,000 volunteers had been recruited for the third phase of the human vaccine trial.
“We are very happy to have seen the best immune response to protection from code 19, not harmful,” he said.
The third phase of this vaccine’s human trial will look at how the vaccine works on a number of people over the age of 18 and to what extent it helps protect people from code 19.
The development of the Code 19 vaccine has accelerated around the world as there are fears that a second wave of the virus could emerge later this winter.
Kate Bingham, chairperson of the British government’s Vaccine Task Force, said she expects significant progress to be made by 2021, even after the Oxford vaccine program is rolled out.
Sarah Gilbert said the Oxford vaccine was expected to be developed soon, but declined to say when it would be available, as it would depend on trial results.
John Bell, a professor of medicine at Oxford University, said the UK needed to be prepared that no vaccine against code 19 might be available by winter and that people should be encouraged to get the flu vaccine to avoid the burden on hospitals.
“There is a lot of reliance on ideas in this whole epidemic and if they can’t be turned into reality, we have to be prepared for a bad situation,” he said.
The British university has already partnered with Swedish-based pharmaceutical company Astrasenka to develop dosage doses of the vaccine, and various organizations such as the Serum Institute of India (SII) and the Coalition are working to save the world from this epidemic. The Epidemic Prevention Innovation (CEPI) and GAVI Vaccine Alliance have also been merged.
The Bill & Melinda Gates Foundation, a charity founded by Microsoft, has announced دینے 750 million for the Code 19 vaccine, which is being developed by the University of Oxford in the United Kingdom.
Millions of dollars provided by Bill Gates will be used to supply 300 million doses of the vaccine, and the first shipment is expected to be ready for delivery by the end of 2020.
Under a separate agreement with SII, one billion doses will be provided to poor and middle class countries, of which 400 million doses will be supplied before 2021.
According to AstraZenka, a total of 2 billion doses of the vaccine will be produced, which will be delivered to non-profit countries during the epidemic.
The 75 750 million investment is part of Bill Gates’ strategy to ensure that the Code 19 vaccine is ready to be delivered.
In April, Bill Gates announced that he would invest billions of dollars in developing a vaccine against the corona virus.
He said billions of dollars would be spent on building factories for the seven best vaccines against the corona virus.
Bill Gates said that 7 of the various vaccines that have gone through the stages of preparation will be selected and factories will be built for their preparation.
“Although in the end we will choose only two of them, we will invest in building separate factories for all the vaccines. Billions of dollars may be lost, but in the end the most effective vaccine factory,” he said. There will definitely be time for that.
He said the simultaneous preparation of the vaccine and the simultaneous construction of the factory were essential for the rapid development of the vaccine.
“We will save many months like this because every month is precious at this time,” he said.
AstraZenka acknowledged that it was not yet possible to say anything about the effectiveness of the vaccine, but that progress would continue.
British scientists expect to complete the human trial by September and introduce the vaccine for general use.
The vaccine was tested on humans on April 23 and initially recruited 1,500 people.
In a small study of 6 monkeys with this experimental vaccine, these animals were given a single dose and it was discovered that they developed antibodies against the virus within 14 days and all of them had protective antibodies within 28 days. Became
When attempts were made to infect these monkeys with the corona virus, the vaccine prevented damage to the lungs and prevented the virus from replicating itself, but it continued to replicate in the nose.
Adrian Hill said that the data on experiments on animals is very encouraging and it has increased the confidence of his team that the results of this test on humans will also be positive.
He said that so far more than a thousand people have been vaccinated during the trial, half of whom have been given experimental vaccines while the rest are working in the control group.
When asked about the progress of the trial, he said, “We can’t comment live, but you can sleep.”
